real-time news and commentary for investors
Wednesday, Dec 19
2012, 8:39 AM
Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon...
Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR)